Transient expression technologies: past, present, and future.
The first protocols describing transient gene expression in mammalian cells for the rapid generation of recombinant proteins emerged more than 10 years ago as an alternative to the establishment of stable, often amplified clonal cell lines, and relieved somewhat the bias against mammalian cell systems as being too complicated, labor intensive, and tedious to serve as a source for tool proteins in industrial research and academia. Over the past decade, these attempts have been refined and optimized, giving rise to expression protocols applicable in every lab in dependence on available tools, equipment, and envisaged outcome. This chapter summarizes the development of transient expression technologies over the past decade up to its current status and provides an outlook into what may be the future of transient technology development.
Novartis Institutes for BioMedical Research, Basel, Switzerland. Sabine.Geisse@novartis.com
Sabine
S
Geisse
Bernd
B
Voedisch
D000818:Animals; D016466:CHO Cells / Q000166:cytology*; D006224:Cricetinae; D003470:Culture Media; D015870:Gene Expression; D005821:Genetic Techniques; D005822:Genetic Vectors; D057809:HEK293 Cells / Q000166:cytology*; D006801:Humans; D055666:Lipopeptides / Q000737:chemistry / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D014162:Transfection / Q000379:methods*
D003470:Culture Media; D055666:Lipopeptides; D011994:Recombinant Proteins